PubRank

Anne N Nafziger

Author PubWeight™ 33.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther 2003 1.42
2 Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002 1.30
3 Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther 2003 1.22
4 Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res 2006 1.12
5 Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol 2002 1.08
6 Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 2006 1.00
7 Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. Br J Clin Pharmacol 2006 0.94
8 Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 2010 0.93
9 Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 2006 0.92
10 Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects. J Clin Pharmacol 2002 0.92
11 Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 2005 0.91
12 Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 2003 0.91
13 Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother 2011 0.91
14 Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet 2010 0.90
15 Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Drug Metab Dispos 2006 0.89
16 Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther 2005 0.89
17 The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol 2006 0.87
18 Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J Clin Pharmacol 2006 0.87
19 Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 2006 0.84
20 Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail. J Clin Pharmacol 2006 0.83
21 Cardiovascular risk factor burden has a stronger association with self-rated poor health in adults in the US than in Sweden, especially for the lower educated. Scand J Public Health 2006 0.83
22 An evaluation of the atkins' diet. Metab Syndr Relat Disord 2003 0.83
23 Quantitative assessment of hepatic blood flow using intravenous indocyanine green. Eur J Clin Pharmacol 2008 0.82
24 Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab Dispos 2006 0.82
25 Self-rated health does not predict 10-year weight change among middle-aged adults in a longitudinal population study. BMC Public Health 2011 0.81
26 Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther 2002 0.80
27 Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. J Clin Pharmacol 2005 0.79
28 Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. J Clin Pharmacol 2004 0.78
29 Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics. Clin Pharmacol Ther 2002 0.78
30 Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J Clin Pharmacol 2004 0.77
31 Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping. Br J Clin Pharmacol 2008 0.77
32 Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. Eur J Clin Pharmacol 2006 0.76
33 Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults. J Clin Pharmacol 2006 0.76
34 Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing. J Clin Pharmacol 2004 0.76
35 Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol 2004 0.76
36 Endogenous 4β-hydroxycholesterol-to-cholesterol ratio is not a validated biomarker for the assessment of CYP3A activity. Drug Metab Dispos 2013 0.75
37 The not so "ideal" body weight-based dosing of Integrilin in obesity. Am Heart J 2012 0.75
38 Validating phenotyping cocktails: more work needs to be done. J Clin Pharmacol 2012 0.75
39 S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction. Ther Drug Monit 2016 0.75
40 Pharmacodynamics of uniform versus nonuniform warfarin dosages. Pharmacotherapy 2008 0.75
41 Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity. Drug Metab Lett 2012 0.75